https://scholars.lib.ntu.edu.tw/handle/123456789/530073
標題: | Renin-angiotensin-aldosterone system inhibitors and risks of severe acute respiratory syndrome coronavirus 2 infection: A systematic review and meta-analysis | 作者: | CHIEH-KAI CHAN YU-SHAN HUANG Liao H.-W. I-JUNG TSAI Sun C.-Y. Pan H.-C. SHIH-CHIEH CHUEH JANN-TAY WANG VIN-CENT WU TZONG-SHINN CHU |
公開日期: | 2020 | 出版社: | Lippincott Williams and Wilkins | 起(迄)頁: | 1563-1571 | 來源出版物: | Hypertension | 摘要: | The viral spike coat protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) engages the human ACE (angiotensin-converting enzyme) 2 cell surface receptor to infect the host cells. Thus, concerns arose regarding theoretically higher risk for coronavirus disease-19 (COVID-19) in patients taking ACE inhibitors/angiotensin II type 1 receptor antagonists (angiotensin receptor blockers [ARBs]). We systematically assessed case-population and cohort studies from MEDLINE (Ovid), Cochrane Database of Systematic Reviews PubMed, Embase, medRXIV, the World Health Organization database of COVID-19 publications, and ClinicalTrials.gov through June 1, 2020, with planned ongoing surveillance. We rated the certainty of evidence according to Cochrane methods and the Grading of Recommendations Assessment, Development and Evaluation approach. After pooling the adjusted odds ratios from the included studies, no significant increase was noted in the risk of SARS-CoV-2 infection by the use of ACE inhibitors (adjusted odds ratio, 0.95 [95% CI, 0.86-1.05]) or ARBs (adjusted odds ratio, 1.05 [95% CI, 0.97-1.14]). However, the random-effects meta-regression revealed that age may modify the SARS-CoV-2 infection risk in subjects with the use of ARBs (coefficient, -0.006 [95% CI, -0.016 to 0.004]), that is, the use of ARBs, as opposed to ACE inhibitors, specifically augmented the risk of SARS-CoV-2 infection in younger subjects (<60 years old). The use of ACE inhibitors might not increase the susceptibility of SARS-CoV-2 infection, severity of disease, and mortality in case-population and cohort studies. Additionally, we discovered for the first time that the use of ARBs, as opposed to ACE inhibitors, specifically augmented the risk of SARS-CoV-2 infection in younger subjects, without obvious effects on COVID-19 outcomes. ? 2020 International Anesthesia Research Society. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85091918286&doi=10.1161%2fHYPERTENSIONAHA.120.15989&partnerID=40&md5=cf0ecd942a7dd242bda5baac9e920236 https://scholars.lib.ntu.edu.tw/handle/123456789/530073 |
ISSN: | 0194-911X | DOI: | 10.1161/HYPERTENSIONAHA.120.15989 | SDG/關鍵字: | angiotensin receptor antagonist; dipeptidyl carboxypeptidase inhibitor; aged; cause of death; drug effect; female; human; hypertension; male; meta analysis; middle aged; pathophysiology; prevalence; prognosis; renin angiotensin aldosterone system; risk assessment; severe acute respiratory syndrome; survival analysis; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Female; Humans; Hypertension; Male; Middle Aged; Prevalence; Prognosis; Renin-Angiotensin System; Risk Assessment; Severe Acute Respiratory Syndrome; Survival Analysis |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。